China Billionaire’s Grand Pharma Buys BlackSwan Vascular For $37.5 Million

Grand Pharmaceutical Group, a China pharmaceuticals supplier whose biggest shareholder is billionaire Hu Kaijun, has agreed to buy 87.5% of U.S.-based vascular drug maker BlackSwan Vascular, Inc. for $37.5 million, Grand Pharmaceutical Group said on Sunday evening.

The move, which is expected to help Grand Pharmaceutical’s global expansion, comes after LavaTM, BlackSwan’s treatment for peripheral vascular arterial hemorrhages, gained premarket approval from the U.S. Food and Drug Administration this month.

BlackSwan, headquartered in Hayward, California, was founded in 2017 by Suresh Pai and Celso Bagaoisan of LamaMed, LLC, and Sanjay Shrivastava of U.S. Vascular, LLC. Sirtex Medical, a provider of therapies for liver cancer, bought BlackSwan for an undisclosed amount in 2020.

Sirtex itself had earlier been acquired by Chinese investment firm CDH and Grand Pharmaceutical in 2018 for $1.4 billion. CDH owns about 10% of Grand; Hu owns approximately 56%.

Grand Pharmaceutical shares have gained 5.6% at the Hong Kong Stock Exchange in the past 12 months.

Hu is president of China Grand Enterprises, whose interests span healthcare, real estate, agriculture and financial services. China Grand is the parent of three publicly traded companies: Grand Pharmaceutical, wholesaler Huadong Medicine and Grand Industrial Holding, a trading business.

Hu, 61, has a fortune worth $3.8 billion on the Forbes Real-Time Billionaires List today.

See related posts:

The 10 Richest Chinese Billionaires 2023

U.S.-China Collaboration Could Cut Development Time, Cost For New Cancer Treatments

U.S. Treasury Secretary Seeks Collaboration, Airs Complaints In Major Speech On China

U.S. Companies Want To De-Risk, Not Decouple, Their China Ties

@rflannerychina